ArticleHPB : the official journal of the International Hepato Pancreato Biliary Association2011
Engineered T cells for pancreatic cancer treatment.
Article in HPB : the official journal of the International Hepato Pancreato Biliary Association, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 60 citations in OpenAlex.
- Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2013Trial
- Role of cell-based therapies in digestive disorders: Obstacles and opportunities.Regenerative therapy · 2025Review
- The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors.Cancers · 2024Review
- Biomarkers for Salvage Therapy in Testicular Germ Cell Tumors.International journal of molecular sciences · 2023Review
- Systemic treatment for advanced pancreatic cancer.World journal of gastrointestinal oncology · 2023Review
- Review
- Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors.Frontiers in immunology · 2023Review
- Developing and validating a survival prediction model based on blood exosomal ceRNA network in patients with PAAD.BMC medical genomics · 2022Article
- Current and future perspectives on CAR-T cell therapy for renal cell carcinoma: A comprehensive review.Investigative and clinical urology · 2022Review
- Novel Redirected T-Cell Immunotherapies for Advanced Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Review
- Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer.Cancers · 2022Review
- Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- High mRNA expression of LY6 gene family is associated with overall survival outcome in pancreatic ductal adenocarcinoma.Oncotarget · 2021Article
- Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors.Frontiers in oncology · 2020Review
- Immunotherapy: Pancreatic Cancer and Extrahepatic Biliary Tract Cancer.Visceral medicine · 2019Review
- Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer.Frontiers in oncology · 2019Review
- Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Anti-Prostate Stem Cell Antigen Cys-Diabody.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018Article
- Emerging trends in the immunotherapy of pancreatic cancer.Cancer letters · 2018Review
- The Potential of CAR T Cell Therapy in Pancreatic Cancer.Frontiers in immunology · 2018Review
- Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers.Human vaccines & immunotherapeutics · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveConventional chemotherapy and radiotherapy produce marginal survival benefits in pancreatic cancer, underscoring the need for novel therapies. The aim of this study is to develop an adoptive T cell transfer approach to target tumours expressing prostate stem cell antigen (PSCA), a tumour-associated antigen that is frequently expressed by pancreatic cancer cells.
methodsExpression of PSCA on cell lines and primary tumour samples was confirmed by immunohistochemistry. Healthy donor- and patient-derived T cells were isolated, activated in vitro using CD3/CD28, and transduced with a retroviral vector encoding a chimeric antigen receptor (CAR) targeting PSCA. The ability of these cells to kill tumour cells was analysed by chromium-51 (Cr(51)) release.
resultsProstate stem cell antigen was expressed on >70% of the primary tumour samples screened. Activated, CAR-modified T cells could be readily generated in clinically relevant numbers and were specifically able to kill PSCA-expressing pancreatic cancer cell lines with no non-specific killing of PSCA-negative target cells, thus indicating the potential efficacy and safety of this approach.
conclusionsProstate stem cell antigen is frequently expressed on pancreatic cancer cells and can be targeted for immune-mediated destruction using CAR-modified, adoptively transferred T cells. The safety and efficacy of this approach indicate that it deserves further study and may represent a promising novel treatment for patients with pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.